Kadirova Nargiza Abdumuhtarovna PhD, is an Assistant of the First Department of Internal Diseases in Family Medicine and the
Basics of Preventive Medicine at the Tashkent State Medicla University. She is researcher in cardiovascular medicine and internal medicine. She obtained her PhD with a dissertation investigating fibrinolytic system disorders in patients with chronic coronary syndrome (stable angina).
Her doctoral research focused on the role of plasminogen activator inhibitor-1 (PAI-1) in patients with chronic coronary syndrome, including those with and without a previous COVID-19 infection. The study evaluated plasma PAI-1 concentrations and their associations with endothelial dysfunction and established cardiovascular risk factors, providing insights into the mechanisms linking impaired fibrinolysis with coronary artery disease. Her previous research also investigated the distribution of PAI-1 gene polymorphisms and their association with susceptibility to ischemic heart disease.
Her research interests include chronic coronary syndrome, coronary artery disease, fibrinolysis, endothelial dysfunction, thrombosis, cardiovascular risk stratification, vascular biomarkers, cardiovascular genetics, and COVID-19-related cardiovascular complications. She has authored more than 10 peer-reviewed scientific publications, two educational manuals, and one monograph, and actively participates in collaborative research on cardiovascular disease mechanisms and evidence-based approache
Kadirova Nargiza Abdumuhtarovna PhD, is an Assistant of the First Department of Internal Diseases in Family Medicine and the
Basics of Preventive Medicine at the Tashkent State Medicla University. She is researcher in cardiovascular medicine and internal medicine. She obtained her PhD with a dissertation investigating fibrinolytic system disorders in patients with chronic coronary syndrome (stable angina).
Her doctoral research focused on the role of plasminogen activator inhibitor-1 (PAI-1) in patients with chronic coronary syndrome, including those with and without a previous COVID-19 infection. The study evaluated plasma PAI-1 concentrations and their associations with endothelial dysfunction and established cardiovascular risk factors, providing insights into the mechanisms linking impaired fibrinolysis with coronary artery disease. Her previous research also investigated the distribution of PAI-1 gene polymorphisms and their association with susceptibility to ischemic heart disease.
Her research interests include chronic coronary syndrome, coronary artery disease, fibrinolysis, endothelial dysfunction, thrombosis, cardiovascular risk stratification, vascular biomarkers, cardiovascular genetics, and COVID-19-related cardiovascular complications. She has authored more than 10 peer-reviewed scientific publications, two educational manuals, and one monograph, and actively participates in collaborative research on cardiovascular disease mechanisms and evidence-based approache